Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03319667
Title Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant (IMROZ)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Sanofi
Indications

multiple myeloma

Therapies

Bortezomib + Dexamethasone + Lenalidomide

Dexamethasone + Isatuximab + Lenalidomide

Bortezomib + Dexamethasone + Isatuximab + Lenalidomide

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.